AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2658438 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin coma (IC) after pharmacotherapy with mageptil, chlorpromazine, melipramine
Number of subjects: 172
Study 2658438 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin coma (IC) after pharmacotherapy with haloperidol, triphtazin, amitriptyline
Number of subjects: 172
Study 2658438 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin coma (IC) after benzodiazepines
Number of subjects: 172
Study 2658438 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin coma (IC) therapy
Number of subjects: 172
Study 2658438 — intervention group
Group type: COMPARATOR
Intervention: Insulin coma (IC) in drug-free patients
Number of subjects: 172
Study 30916655 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game (Tobbstop) used for 3 months
Number of subjects: 42
Study 30916655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no serious game)
Number of subjects: 42
Study 28622178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural Puncture Epidural (DPE) with 0.125% bupivacaine and 50 μg fentanyl
Number of subjects: 80
Study 28622178 — intervention group
Group type: COMPARATOR
Intervention: Lumbar Epidural (LE) with 0.125% bupivacaine and 50 μg fentanyl
Number of subjects: 80
Study 26951210 — intervention group
Group type: EXPERIMENTAL
Intervention: What Were We Thinking (WWWT) programme
Number of subjects: 400
Study 26951210 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 25262346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-chi intervention for 12 weeks
Number of subjects: 153
Study 25262346 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention for 12 weeks
Number of subjects: 153
Study 25262346 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 153
Study 22542356 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (anterior/apical with or without posterior repairs)
Number of subjects: 597
Study 22542356 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups I-III (concomitant surgeries)
Number of subjects: 597
Study 22542356 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (nonprolapse procedures)
Number of subjects: 597
Study 22542356 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups I and II (anterior/apical repairs and posterior repairs)
Number of subjects: 597
Study 22542356 — intervention group
Group type: COMPARATOR
Intervention: Group IV (no concomitant surgeries)
Number of subjects: 597
Study 20418251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic rehabilitation (n=95)
Number of subjects: 296
Study 20418251 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive listening (n=101)
Number of subjects: 296
Study 20418251 — intervention group
Group type: COMPARATOR
Intervention: General practitioner treatment as usual (n=100)
Number of subjects: 296
Study 17934448 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide YY3-36 (PYY) at high plasma concentrations
Number of subjects: 0
Study 17934448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of PYY
Number of subjects: 0
Study 16041731 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytotherapeutic agent (PA) - Matricariae recutita, Foeniculum vulgare and Melissa officinalis, administered twice a day for 1 week.
Number of subjects: 93
Study 16041731 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice a day for 1 week.
Number of subjects: 93
Study 12466166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear corneal phacoemulsification and implantation of a foldable intraocular lens
Number of subjects: 47
Study 10027360 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative tests for small fibre neuropathy in patients with STC
Number of subjects: 33
Study 10027360 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative tests for axon-reflex sweating in patients with STC
Number of subjects: 33
Study 10027360 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative tests for sensory fibre dysfunction in patients with STC
Number of subjects: 33
Study 10027360 — intervention group
Group type: COMPARATOR
Intervention: Comparison with matched control subjects
Number of subjects: 33
Study 10027360 — intervention group
Group type: COMPARATOR
Intervention: Comparison with diabetic patients with gastrointestinal symptoms
Number of subjects: 33
Study 8749724 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral treatment with adjunct therapies (acupuncture, anticraving medication, brainwave therapy)
Number of subjects: 0
Study 8749724 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment sessions attended
Number of subjects: 0
Study 8749724 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct therapies (acupuncture, anticraving medication, brainwave therapy)
Number of subjects: 0
Study 8749724 — intervention group
Group type: COMPARATOR
Intervention: Neurobehavioral treatment alone
Number of subjects: 0
Study 2201988 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) for 3 weeks
Number of subjects: 0
Study 2201988 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine (T4) for 3 weeks
Number of subjects: 0
Study 2201988 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 and T4
Number of subjects: 0
Study 7389385 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diacetylrhein per day
Number of subjects: 12
Study 7389385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30908361 — intervention group
Group type: EXPERIMENTAL
Intervention: TCA→FRF
Number of subjects: 67
Study 30908361 — intervention group
Group type: EXPERIMENTAL
Intervention: FRF→TCA
Number of subjects: 67
Study 30908361 — intervention group
Group type: COMPARATOR
Intervention: FRF
Number of subjects: 67
Study 30908361 — intervention group
Group type: COMPARATOR
Intervention: TCA20%
Number of subjects: 67
Study 27937053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg single oral dose
Number of subjects: 196
Study 27937053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 50 μM incubation
Number of subjects: 196
Study 26310692 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once-weekly
Number of subjects: 685
Study 26310692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study 24530652 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose testosterone administration
Number of subjects: 0
Study 22954906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse decoding algorithm for neuronal activity
Number of subjects: 23
Study 22954906 — intervention group
Group type: COMPARATOR
Intervention: Existing methods for decoding neuronal activity
Number of subjects: 23
Study 19237980 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL 10 ml/kg
Number of subjects: 100
Study 19237980 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL 30 ml/kg
Number of subjects: 100
Study 17879563 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study 17879563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15006108 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood (FOB) screening
Number of subjects: 153000
Study 15006108 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic presentation (Control)
Number of subjects: 153000
Study 12439474 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional appliances
Number of subjects: 6
Study 12439474 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 6
Study 9821904 — intervention group
Group type: EXPERIMENTAL
Intervention: General physical training program (twice a week for 3 months, including group training and a daily home exercise program)
Number of subjects: 25
Study 9821904 — intervention group
Group type: EXPERIMENTAL
Intervention: General physical training program
Number of subjects: 25
Study 7867678 — intervention group
Group type: EXPERIMENTAL
Intervention: mizolastine 40 mg
Number of subjects: 24
Study 7867678 — intervention group
Group type: EXPERIMENTAL
Intervention: mizolastine 20 mg
Number of subjects: 24
Study 7867678 — intervention group
Group type: EXPERIMENTAL
Intervention: mizolastine 10 mg
Number of subjects: 24
Study 7867678 — intervention group
Group type: EXPERIMENTAL
Intervention: mizolastine 5 mg
Number of subjects: 24
Study 7867678 — intervention group
Group type: COMPARATOR
Intervention: clemastine 2 mg
Number of subjects: 24
Study 2572902 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pamidronate as a single intravenous infusion
Number of subjects: 48
Study 2572902 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clodronate as a single intravenous infusion
Number of subjects: 48
Study 2572902 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate as three infusions of 7.5 mg/kg per day for three consecutive days
Number of subjects: 48
Study 792994 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline inhaled via IPPB
Number of subjects: 12
Study 792994 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg terbutaline inhaled via IPPB
Number of subjects: 12
Study 31823444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40 or 80 mg/day)
Number of subjects: 384
Study 31823444 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (2, 4 or 6 mg/day)
Number of subjects: 384
Study 31823444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 384
Study 30771686 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.4 g/d)
Number of subjects: 24
Study 30771686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27306854 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium care
Number of subjects: 125
Study 27306854 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study 25822197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic orthosis (vacuum-fit flexible but blocked orthosis)
Number of subjects: 29
Study 25822197 — intervention group
Group type: COMPARATOR
Intervention: Dorsal plaster splint
Number of subjects: 29
Study 22984950 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal time estimates in Experiment 1
Number of subjects: 0
Study 22984950 — intervention group
Group type: EXPERIMENTAL
Intervention: TBPM task without external clock in Experiment 2
Number of subjects: 0
Study 22984950 — intervention group
Group type: EXPERIMENTAL
Intervention: TBPM task with access to a clock in Experiment 2
Number of subjects: 0
Study 21419297 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI) followed by a final rinse with 0.2% chlorhexidine (CHX)
Number of subjects: 0
Study 21419297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedström filing
Number of subjects: 0
Study 21419297 — intervention group
Group type: COMPARATOR
Intervention: Chemomechanical preparation
Number of subjects: 0
Study 21419297 — intervention group
Group type: EXPERIMENTAL
Intervention: Final rinse with CHX after PUI
Number of subjects: 0
Study 19289928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletters
Number of subjects: 225
Study 19289928 — intervention group
Group type: COMPARATOR
Intervention: Generic newsletters
Number of subjects: 225
Study 17353334 — intervention group
Group type: EXPERIMENTAL
Intervention: High creatine intake with diet restrictions to reduce guanidinoacetate synthesis in GAMT‐d patients.
Number of subjects: 5
Study 17353334 — intervention group
Group type: EXPERIMENTAL
Intervention: Different creatine intakes in AGAT‐d patients.
Number of subjects: 5
Study 15347339 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (three times weekly)
Number of subjects: 55
Study 15347339 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (five times weekly)
Number of subjects: 55
Study 15347339 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 55
Study 11493504 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 50% nitrous oxide
Number of subjects: 64
Study 11493504 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane with oxygen only (control)
Number of subjects: 64
Study 9568413 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral at 2.5 mg/kg/day or equivalent to pre-conversion SIM dosage
Number of subjects: 58
Study 9568413 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun (SIM)
Number of subjects: 58
Study 8929936 — intervention group
Group type: EXPERIMENTAL
Intervention: Social model residential program providing integrated mental health and substance abuse treatment
Number of subjects: 276
Study 8929936 — intervention group
Group type: EXPERIMENTAL
Intervention: Community‐based nonresidential program using the same social model approach
Number of subjects: 276
Study 8929936 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no intervention but free to access other community services
Number of subjects: 276
Study 2198731 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (mean dosage 25 +/- 10 mg/day)
Number of subjects: 29
Study 2198731 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (mean dosage 77 +/- 26 mg/day)
Number of subjects: 29
Study 403149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of tritium-labeled ergot alkaloids
Number of subjects: 6
Study 403149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of tritium-labeled ergot alkaloids
Number of subjects: 6
Study 29736892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Fatigability Scale (PFS)
Number of subjects: 79
Study 27583439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid solutions delivered separately (Group 1)
Number of subjects: 60
Study 27583439 — intervention group
Group type: COMPARATOR
Intervention: Lipid solutions in mixture with TPN solutions (Group 2)
Number of subjects: 60
Study 25887959 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Programme for the Last Days of Life
Number of subjects: 0
Study 25887959 — intervention group
Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 0
Study 23360528 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (Betadine) soaked surgical gauze
Number of subjects: 49
Study 23360528 — intervention group
Group type: COMPARATOR
Intervention: Saline soaked surgical gauze
Number of subjects: 49
Study 21366694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus melphalan-prednisone (VMP)
Number of subjects: 682
Study 21366694 — intervention group
Group type: COMPARATOR
Intervention: Melphalan-prednisone (MP)
Number of subjects: 682
Study 19681938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay bone grafting
Number of subjects: 20
Study 19681938 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay bone grafting
Number of subjects: 20
Study 17135457 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 64 mmol/day
Number of subjects: 0
Study 15520986 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (intramuscular administration)
Number of subjects: 80
Study 15520986 — intervention group
Group type: COMPARATOR
Intervention: Control (able-bodied subjects)
Number of subjects: 80
Study 15086492 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 0
Study 15086492 — intervention group
Group type: COMPARATOR
Intervention: Non-African Americans
Number of subjects: 0
Study 10908985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucomyst (NAC)
Number of subjects: 75
Study 10908985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9316363 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut and coconut oil consumption
Number of subjects: 48
Study 9316363 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study 8418313 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by standard therapy with surgery and/or radiation
Number of subjects: 0
Study 8418313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus fluorouracil (5-FU) followed by radiotherapy
Number of subjects: 0
Study 8418313 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative cisplatin plus 5-FU prior to radiotherapy
Number of subjects: 0
Study 8418313 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy alone
Number of subjects: 0
Study 8418313 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus radiotherapy
Number of subjects: 0
Study 8418313 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical modulation of 5-FU with leucovorin and biologic response modifiers such as interferon
Number of subjects: 0
Study 8418313 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0
Study 3080575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (25 mg/kg/day)
Number of subjects: 8
Study 3080575 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (2 mg/kg/day)
Number of subjects: 8
Study 2682120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg over 15 minutes)
Number of subjects: 8
Study 2682120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31653801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant elbow flexors training (EFlex)
Number of subjects: 43
Study 31653801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant leg press training (LP)
Number of subjects: 43
Study 31653801 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 30847474 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg maintenance dose starting at Week 6
Number of subjects: 0
Study 30847474 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg maintenance dose for early nonresponders <80 kg
Number of subjects: 0
Study 30847474 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg maintenance dose for early nonresponders
Number of subjects: 0
Study 30847474 — intervention group
Group type: EXPERIMENTAL
Intervention: Early responders
Number of subjects: 0
Study 28100440 — intervention group
Group type: EXPERIMENTAL
Intervention: Web Behavior Change Program for Activity (Web‐BCPA) in combination with multimodal rehabilitation (MMR)
Number of subjects: 19
Study 26286532 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (0, 6, 12, or 18 visits)
Number of subjects: 400
Study 26286532 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment predictor models
Number of subjects: 400
Study 26286532 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment pain alone
Number of subjects: 400
Study 26286532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment predictor models
Number of subjects: 400
Study 26286532 — intervention group
Group type: COMPARATOR
Intervention: Light-massage control (at remaining visits)
Number of subjects: 400
Study 23464382 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive episiotomy
Number of subjects: 0
Study 23464382 — intervention group
Group type: COMPARATOR
Intervention: Routine episiotomy
Number of subjects: 0
Study 21127322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell infusion (BMC)
Number of subjects: 101
Study 21127322 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 21127322 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC group
Number of subjects: 101
Study 19661218 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CD)
Number of subjects: 142
Study 19661218 — intervention group
Group type: COMPARATOR
Intervention: Acetate dialysate (AD)
Number of subjects: 142
Study 17439763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia (HT) combined with radiation therapy
Number of subjects: 100
Study 17439763 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 100
Study 14634864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 90 mg/m(2)/day for 42 days
Number of subjects: 56
Study 14634864 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 56
Study 11457531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin‐tetrapeptide (CCK‐4) administered intravenously
Number of subjects: 0
Study 9631379 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac (together with diazepam)
Number of subjects: 206
Study 9631379 — intervention group
Group type: COMPARATOR
Intervention: pethidine
Number of subjects: 206
Study 9631379 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (non-steroidal anti-inflammatory drugs)
Number of subjects: 206
Study 9631379 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 206
Study 8004292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 ppm ozone in filtered air (FA)
Number of subjects: 21
Study 8004292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ppm ozone in filtered air (FA)
Number of subjects: 21
Study 8004292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.40 ppm ozone in filtered air (FA)
Number of subjects: 21
Study 8004292 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA) alone
Number of subjects: 21
Study 2591089 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-in-water emulsion applied twice daily for 7 days
Number of subjects: 16
Study 2591089 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated forearm)
Number of subjects: 16
Study 2591089 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-in-water emulsion
Number of subjects: 16
Study 1218336 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I fibrinogen test
Number of subjects: 72
Study 1218336 — intervention group
Group type: COMPARATOR
Intervention: Venography
Number of subjects: 72
Study 1218336 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both techniques
Number of subjects: 72
Study 27736011 — intervention group
Group type: EXPERIMENTAL
Intervention: modified papilla preservation technique with titanium-reinforced expanded-polytetrafluoroethylene (ePTFE) membranes (MPPT Tit, N = 15)
Number of subjects: 45
Study 27736011 — intervention group
Group type: EXPERIMENTAL
Intervention: access flap with expanded-PTFE membranes (Flap-ePTFE, N = 15)
Number of subjects: 45
Study 27736011 — intervention group
Group type: COMPARATOR
Intervention: access flap alone (Flap, N = 15)
Number of subjects: 45